<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Expression of <z:mp ids='MP_0001799'>viral</z:mp> genes in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells of the virus-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> could provide highly selective ways of targeting expression of therapeutic vectors to the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="1" pm="."><plain>The ubiquitous presence of EBNA-1 in Epstein-Barr virus-associated <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> could be used to activate expression constructs containing oriP in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="2" pm="."><plain>This is demonstrated for a variety of model systems including epithelial cells, which would be the target cell type for the treatment of undifferentiated nasopharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp>, a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> that always contains Epstein-Barr virus in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumour</z:e> cells </plain></SENT>
<SENT sid="3" pm="."><plain>Combining an oriP/EBNA-1-dependent Epstein-Barr virus Cp promoter with delayed assay of reporter gene, a 108-fold differential was obtained between the activity of a transfected plasmid in cells containing or lacking EBNA-1 expression </plain></SENT>
<SENT sid="4" pm="."><plain>This might provide sufficient specificity for a successful in vivo therapeutic strategy </plain></SENT>
</text></document>